The commercial success of GLP-1 receptor agonists such as Ozempic, Wegovy, and Rybelsus, along with dual GIP/GLP-1 receptor agonists including Mounjaro and Zepbound, has significantly increased the requirement for large-scale, high-quality peptide API manufacturing
A 2.29-fold increase ranks this gene among the top eight most affected by BPC-157 treatment in microarray analysis
Our program offers the support and tools needed to help you sustain your progress, even after completing treatment
If a vial freezes, the product should be discarded
Association of obesity with survival outcomes in patients with cancer: a systematic review and meta-analysis
We emphasize a patient-centered approach, combining Ozempic therapy with lifestyle modifications and ongoing support to help you achieve lasting results